Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
NASDAQ:CRVO

CervoMed Q3 2023 Earnings Report

CervoMed logo
$9.43 +0.11 (+1.19%)
As of 10:43 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

CervoMed EPS Results

Actual EPS
-$0.70
Consensus EPS
-$0.95
Beat/Miss
Beat by +$0.25
One Year Ago EPS
N/A

CervoMed Revenue Results

Actual Revenue
$1.53 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

CervoMed Announcement Details

Quarter
Q3 2023
Date
11/13/2023
Time
Before Market Opens
Conference Call Date
Monday, November 13, 2023
Conference Call Time
7:00AM ET

Upcoming Earnings

CervoMed's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

CervoMed's Q3 2023 Press ReleasePress Release
(8-K)
CervoMed's Q3 2023 Quarterly reportQuarterly report
(10-Q)

CervoMed Earnings Headlines

Research Analysts Set Expectations for CervoMed Q3 Earnings
August 22, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30290580
D. Boral Capital Forecasts Strong Price Appreciation for CervoMed (NASDAQ:CRVO) Stock
August 19, 2025  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30285845
Trump’s AI Agenda: The 9 stocks poised to benefit most
While many are busy chasing the usual AI trends, a bigger opportunity is quietly brewing—and most are missing it. Imagine a major shift in how and where AI is built, opening up incredible wealth opportunities for those in the know. I’ve found 9 AI companies primed to lead this change. These aren’t the tired “AI hype” stocks; they’re companies with real US operations, proven revenue growth, and deep AI integration.tc pixel
August 29 at 2:00 AM  |  StockEarnings (Ad)
CervoMed price target raised to $31 from $15 at D. Boral Capital
August 18, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/cervomed-price-target-raised-to-31-from-15-at-d-boral-capital/ar-AA1KKbqM
CervoMed Reports Promising Trial Results and Financial Update
August 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/cervomed-reports-promising-trial-results-and-financial-update/ar-AA1Kmor2
CervoMed price target lowered to $16 from $20 at Roth Capital
August 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/cervomed-price-target-lowered-to-16-from-20-at-roth-capital/ar-AA1Kok2c
See More CervoMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email.

About CervoMed

CervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

View CervoMed Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles